Materion Corporation (MTRN)vsVersamet Royalties Corporation Common Stock (VMET)
MTRN
Materion Corporation
$290.05
+4.24%
BASIC MATERIALS · Cap: $4.39B
VMET
Versamet Royalties Corporation Common Stock
$10.25
+5.13%
BASIC MATERIALS · Cap: $933.87M
Smart Verdict
WallStSmart Research — data-driven comparison
Materion Corporation generates 3366% more annual revenue ($1.92B vs $55.27M). VMET leads profitability with a 58.4% profit margin vs 4.0%. VMET trades at a lower P/E of 28.7x. VMET earns a higher WallStSmart Score of 60/100 (C+).
MTRN
Buy54
out of 100
Grade: C-
VMET
Buy60
out of 100
Grade: C+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 30.8% year-over-year
Keeps 58 of every $100 in revenue as profit
Strong operational efficiency at 90.6%
Revenue surging 594.0% year-over-year
Earnings expanding 573.0% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
4.0% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Moderate valuation
Smaller company, higher risk/reward
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MTRN
The strongest argument for MTRN centers on Revenue Growth. Revenue growth of 30.8% demonstrates continued momentum. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : VMET
The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.4% and operating margin at 90.6%. Revenue growth of 594.0% demonstrates continued momentum.
Bear Case : MTRN
The primary concerns for MTRN are Profit Margin, Piotroski F-Score, P/E Ratio. A P/E of 57.8x leaves little room for execution misses. Thin 4.0% margins leave little buffer for downturns.
Bear Case : VMET
The primary concerns for VMET are P/E Ratio, Market Cap, Altman Z-Score.
Key Dynamics to Monitor
MTRN profiles as a hypergrowth stock while VMET is a growth play — different risk/reward profiles.
VMET is growing revenue faster at 594.0% — sustainability is the question.
MTRN generates stronger free cash flow (41M), providing more financial flexibility.
Monitor OTHER INDUSTRIAL METALS & MINING industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VMET scores higher overall (60/100 vs 54/100), backed by strong 58.4% margins and 594.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Materion Corporation
BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA
Materion Corporation (MTRN) is a premier provider of advanced materials, specializing in high-performance metals and alloys essential for key sectors including aerospace, defense, telecommunications, and electronics. The company is recognized for its innovative applications of beryllium and copper, along with a diverse portfolio of specialty coatings that adhere to the highest industry standards. Driven by a robust commitment to research and development and bolstered by strategic partnerships, Materion is well-positioned to enhance its competitive edge and achieve sustainable growth through customized, innovative solutions tailored to meet the evolving needs of its varied clientele.
Versamet Royalties Corporation Common Stock
BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA
Viamet Pharmaceuticals Corp (VMET) is an innovative biopharmaceutical company dedicated to the development of advanced therapeutics targeting serious diseases, particularly in the areas of fungal infections and oncology, utilizing its proprietary metalloenzyme-based technology platform. With a robust and diversified clinical pipeline supported by strategic partnerships and a comprehensive intellectual property portfolio, Viamet is strategically positioned for significant growth. The company remains focused on addressing critical unmet medical needs and is committed to enhancing shareholder value through continued therapeutic advancements in its specialized areas.
Compare with Other OTHER INDUSTRIAL METALS & MINING Stocks
Want to dig deeper into these stocks?